Acta Neuropsychiatrica最新文献

{"title":"A comprehensive systematic review of human trials investigating herbal treatments for Alzheimer's disease and dementia.","authors":"Katarzyna A Kaczmarek-Kryszak, Małgorzata Dobrzyńska, Michalina Banaszak, Sławomira Drzymała-Czyż","doi":"10.1017/neu.2026.10085","DOIUrl":"https://doi.org/10.1017/neu.2026.10085","url":null,"abstract":"<p><strong>Objective: </strong>Dementia is a group of symptoms, characterized by a loss of cognition that interferes with everyday tasks, difficulty focusing, planning, problem solving, and behavioral changes, such as apathy, anxiety, or depression. The leading cause of dementia is Alzheimer's disease, but vascular dementia or mild cognitive impairment are also frequently occurring. There are six drugs legislated in Europe for use in the treatment of dementia. There are unmet clinical needs to find more effective, better tolerated or complementary therapeutic options. The aim of this study is to comprehensively analyze the results of clinical trials and other human studies regarding the efficacy and safety of herbal interventions used in patients with dementia.</p><p><strong>Methods: </strong>We enrolled a total of 48 studies for this systematic review, of which 27 were included into the statistical analysis of effect size (Cohen's <i>d</i>).</p><p><strong>Results: </strong>We found significant improvements mainly after administration of <i>Ginkgo biloba, Crocus sativus, Salvia officinalis,</i> and <i>Melissa officinalis</i>.It should be emphasized that some herbs and herbal formulations demonstrated efficacy comparable to that of donepezil, a widely used and approved medication, suggesting potential for phytopharmaceutical therapies as complementary approaches. In some studies, the observed effects were similar to those reported for conventional treatments, indicating promising directions for further research in Alzheimer's disease and dementia.</p><p><strong>Conclusion: </strong>In light of the evidence, phytopharmaceuticals have a promising role as a co-therapeutic option or alternative for patients with dementia who do not tolerate or have contraindications to standard medications. However, further research is necessary to translate these initial promising results into clinical practice.</p><p><strong>Summations: </strong>Phytopharmaceuticals have a promising role as a complementary or alternative option for dementia patients who cannot tolerate or respond to standard medications. Certain phytopharmaceuticals demonstrated comparable short-term symptomatic effects to standard treatments in small trials; however, evidence is insufficient to support equivalence or superiority.</p><p><strong>Considerations: </strong>Many of the studies reviewed are limited by very small sample sizes, which is associated with a high risk of bias when interpreting large effect sizes (Cohen's <i>d</i>). The short duration of interventions (often only 3 to 6 months) is insufficient to assess whether phytotherapeutics can constitute disease-modifying treatments (DMTs).</p>","PeriodicalId":48964,"journal":{"name":"Acta Neuropsychiatrica","volume":" ","pages":"1-55"},"PeriodicalIF":2.5,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147845043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age-Dependent Increase in Peripheral Neuropeptide Y with No Cross-Sectional Link to Depression.","authors":"Mehdi Hajivali Dahlaki, Mohammad Zayeed Bin Alam, Marit Nyholm Nielsen, Henriette Nørmølle Buttenschøn, Michael Winterdahl","doi":"10.1017/neu.2026.10084","DOIUrl":"https://doi.org/10.1017/neu.2026.10084","url":null,"abstract":"<p><strong>Background: </strong>Neuropeptide Y (NPY) has been implicated in stress resilience and depression, yet findings on circulating levels in major depressive disorder (MDD) remain inconsistent, possibly due to confounders such as age, sex, and body mass index (BMI). This study aimed to assess NPY concentrations in individuals with MDD and in matched controls from the Danish PRISME cohort of public-sector employees.</p><p><strong>Methods: </strong>We investigated plasma NPY (p-NPY) concentrations in 77 adults with a current ICD-10 diagnosis of MDD and 77 age- and sex-matched controls. The plasma samples were analysed using a commercial ELISA kit. A general linear model examined the effects of group, age, sex, and BMI, including a sex-by-group interaction. Plasma NPY values were log₁₀-transformed prior to analysis.</p><p><strong>Results: </strong>p-NPY concentrations did not differ significantly between MDD and controls (p = .785). No main effect of sex or sex-by-group interaction was observed (all p > .17), and BMI was unrelated to p-NPY (p = .917). By contrast, age was a strong predictor (β = .38, p < .001), explaining 13% of the variance in p-NPY levels.</p><p><strong>Conclusions: </strong>In this community-based sample of high-functioning individuals with MDD, we found no evidence of altered p-NPY concentrations compared with matched controls. Instead, age emerged as a robust determinant of circulating NPY levels, independent of depression status and BMI, after adjustment for sex. These findings suggest that peripheral NPY variation may be more strongly related to demographic factors than to depression per se in this type of cohort and may not generalise to more severe or chronic forms of the disorder.</p>","PeriodicalId":48964,"journal":{"name":"Acta Neuropsychiatrica","volume":" ","pages":"1-18"},"PeriodicalIF":2.5,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147844983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The belief that certain illnesses can only be treated by traditional healers: A qualitative study exploring the \"traditional illness\" Xifula in Limpopo, South Africa.","authors":"Michael Galvin, Lezanie Coetzee, Patricia Leshabana, Nthabiseng Masebe, Aneesa Moolla, Peter C Rockers, Denise Evans","doi":"10.1017/neu.2026.10083","DOIUrl":"https://doi.org/10.1017/neu.2026.10083","url":null,"abstract":"<p><strong>Background: </strong>In Africa, bewitchment is described as a moral framework that helps individuals and societies make sense out of disease and misfortune. Numerous African belief systems attribute difficult-to-treat health problems to bewitchment, rather than a conventional medical diagnosis, especially if biomedical doctors are unable to resolve the condition. This study examines one such illness, known as <i>xifula</i>, in rural Limpopo Province, South Africa.</p><p><strong>Methods: </strong>Using convenience sampling, 95 participants (≥18 years old) were interviewed to gauge their knowledge of the condition known as <i>xifula.</i> Data was analysed using NVivo software.</p><p><strong>Findings: </strong><i>Xifula</i> is a cultural concept of distress related to bewitchment. The most common symptom of <i>xifula</i> is swelling of the legs or hands, followed by chronic headaches. Participants noted that <i>xifula</i> can start as a minor ailment, but then grows into a larger problem. After a long period without healing, however, <i>xifula</i> can begin to represent a significant threat to the individual's health. Nearly all participants noted that <i>xifula</i> cannot be treated by Western biomedical professionals and instead requires a traditional healer to treat the condition.</p><p><strong>Interpretation: </strong>This research highlights the importance of context-specific education about the diagnosis and treatment of common ailments, as beliefs about afflictions, their causes, and appropriate treatments suggest a need for tailored information. As biomedical and traditional healthcare currently exist as parallel, siloed structures of diagnosis and treatment in Africa, there should also be efforts to bridge the divide between the two.</p><p><strong>Funding: </strong>This study was funded by a grant from the John Templeton Foundation.</p>","PeriodicalId":48964,"journal":{"name":"Acta Neuropsychiatrica","volume":" ","pages":"1-18"},"PeriodicalIF":2.5,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147786333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bilateral DLPFC Transcranial Direct Current Stimulation for Mood and Motor Symptoms in Parkinson's Disease: A Preliminary Study.","authors":"Boram Chae, Jae-Ha Song, Do-Young Kwon, Ho-Kyoung Yoon","doi":"10.1017/neu.2026.10082","DOIUrl":"https://doi.org/10.1017/neu.2026.10082","url":null,"abstract":"<p><strong>Objectives: </strong>Patients with Parkinson's disease (PD) suffer from interrelated motor and non-motor symptoms. While most research focuses on motor improvement, this study investigated whether targeting mood via sequential bilateral dorsolateral prefrontal cortex (DLPFC) tDCS could favorably affect motor function in patients maintaining a stable medication 'ON' state. Additionally, we employed wearable smart devices to objectively evaluate real-world changes in daily activity and sleep patterns, complementing traditional clinician-rated scales.</p><p><strong>Methods: </strong>PD patients with mild-to-moderate depressive symptoms were enrolled. All participants completed a 7-day baseline monitoring period using a smart band. Participants received ten sessions of bilateral tDCS targeting the DLPFC (anode F3, cathode F4) at 2 mA for 30 minutes, three times a week. Clinical assessments and smart band monitoring were repeated during the final week of treatment. Pre-post changes and correlations were analyzed while controlling for potential confounders.</p><p><strong>Results: </strong>Following tDCS, it was significant improvements in K-MADRS, STAI, AS, UPDRS part III, and PDQ-39. Smart device data showed a significant increase in daily step counts after treatment, while changes in physical activity time and sleep duration were not significant. Changes in step count were strongly correlated with improvements in apathy, and this relationship remained significant after confounding variables (rho = -0.76, p < 0.001).</p><p><strong>Conclusions: </strong>Bilateral DLPFC tDCS significantly improved mood and motor function in patients with PD. Smart band data further showed an increase in daily step counts after the intervention, with reductions in apathy. These findings suggest that tDCS may enhance goal-directed behavior by modulating mood-related pathways, highlighting apathy as an important therapeutic target in PD.</p>","PeriodicalId":48964,"journal":{"name":"Acta Neuropsychiatrica","volume":" ","pages":"1-24"},"PeriodicalIF":2.5,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147786138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of alpha-pinene on anxiety behaviors and TLR4/MYD88/NF-kB pathway in the hippocampus in the reserpine-induced anxiety model in rats.","authors":"Matin Nasiri, Kaveh Rahimi, Zohreh Ghotbeddin","doi":"10.1017/neu.2026.10080","DOIUrl":"https://doi.org/10.1017/neu.2026.10080","url":null,"abstract":"<p><strong>Objective: </strong>Anxiety disorders are prevalent neuropsychiatric conditions associated with neuroinflammation and altered cytokine signaling in the hippocampus. This study aimed to evaluate the anxiolytic-like effects of alpha-pinene and its potential modulation of hippocampal neuroinflammatory pathways in a reserpine-induced anxiety model.</p><p><strong>Methods: </strong>Adult male Wistar rats were randomly assigned to four groups: control (vehicle), reserpine (0.5 mg/kg, i.p.), and reserpine co-treated with alpha-pinene at 50 or 100 mg/kg. Treatments were administered intraperitoneally for 10 consecutive days. Behavioral assays-including the Open Field Test, Elevated Plus Maze, and Light/Dark Box Test-assessed locomotor activity and anxiety-like behaviors. Following testing, hippocampal tissues were collected for molecular analyses, including real-time PCR for TLR4, MyD88, and NF-κB expression, and ELISA quantification of IL-1β and IL-6 levels.</p><p><strong>Results: </strong>Reserpine induced robust anxiety-like behaviors, accompanied by significant upregulation of TLR4, MyD88, and NF-κB expression and increased hippocampal IL-1β and IL-6. Alpha-pinene treatment at both doses significantly attenuated anxiety-like behaviors and reduced neuroinflammatory markers, suggesting involvement of the TLR4/MyD88/NF-κB pathway.</p><p><strong>Conclusion: </strong>Alpha-pinene exhibits anxiolytic-like effects in reserpine-treated rats, potentially via suppression of hippocampal neuroinflammation, supporting further investigation into its therapeutic potential for anxiety disorders.</p>","PeriodicalId":48964,"journal":{"name":"Acta Neuropsychiatrica","volume":" ","pages":"1-23"},"PeriodicalIF":2.5,"publicationDate":"2026-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147786264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heroin assessment in Spanish population-based studies: the state of the art and recommendations for the future.","authors":"A Teijeiro, A García-González, N Mourino, S Correia, C Guerra-Tort, C Candal-Pedreira, G García, J Rey-Brandariz, M Pérez-Ríos","doi":"10.1017/neu.2026.10081","DOIUrl":"https://doi.org/10.1017/neu.2026.10081","url":null,"abstract":"<p><strong>Introduction: </strong>Estimating the prevalence of use of substances such as heroin remains a challenge. The aim of this study is to identify the scientific publications in Spain that have used surveys to investigate heroin use, to describe their methodology and to contrast the formulation of the questions with users' input on key aspects associated with use.</p><p><strong>Methods: </strong>A scoping review was conducted until November 2024 in MEDLINE (Ovid), EMBASE and Web of Science. The review included questionnaire-based research studies assessing heroin use in Spain. Information on study, population, data collection and consumption characteristics was compiled from each included study. In addition, in-depth interviews were conducted with Spanish heroin current users and ex-users.</p><p><strong>Results: </strong>Twenty-nine questionnaire-based research studies assessing heroin use in Spain were identified, none of them were specifically oriented to estimate and characterize heroin use at the population level. Most of the studies focused on specific population groups, mainly drug users, students, or inmates. The majority addressed lifetime, past-year, and past-month use, although users found the past 3 or 6 months more relevant. Few studies explored other use characteristics; however, interviews with heroin ex-users highlighted the importance of factors like route of administration and age of first use.</p><p><strong>Conclusions: </strong>Studies on heroin use differ in terms of population, geographic scope, time frame, and data collection methods. Incorporating users' perspectives in the design of surveys is essential to enhance standardization and optimize data comparability.</p>","PeriodicalId":48964,"journal":{"name":"Acta Neuropsychiatrica","volume":" ","pages":"1-26"},"PeriodicalIF":2.5,"publicationDate":"2026-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147786259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improved dietary control results in improvements in indices of white matter structure in adults with phenylketonuria: the ReDAPT study.","authors":"Matthew Jy Kang, Christopher Adamson, Charles B Malpas, Toby Winton-Brown, Nicholas Burgess, Timothy Fazio, Dennis Velakoulis, Patricia Desmond, Vijay Venkatraman, Gerard De Jong, Mark Walterfang","doi":"10.1017/neu.2026.10078","DOIUrl":"https://doi.org/10.1017/neu.2026.10078","url":null,"abstract":"<p><strong>Objective: </strong>We tested the hypothesis that resuming dietary control in early-treated phenylketonuria (PKU) is associated with improvements in white matter integrity, using data from the ReDAPT study, which previously demonstrated cognitive and psychiatric improvements with reduced phenylalanine (Phe) levels.</p><p><strong>Methods: </strong>We re-initiated dietary control for early-treated patients with PKU and assessed the T1w/T2w ratio from standard T1- and T2-weighted magnetic resonance images, a marker of myelination and microstructural integrity. General linear mixed model (GLMM) analyses were performed to assess change in the T1w/T2w ratio from baseline over twelve months after resumption of dietary control.</p><p><strong>Results: </strong>Seven participants (mean age 31 years; five female) with neuroimaging were included, with a mean of 16 years off diet and baseline Phe levels of 1157 µmol/L. GLMM analyses showed significant increases in T1w/T2w ratio over time for the whole brain (β = 0.47 [95%CI = 0.28, 0.66]), left hemisphere (β = 0.36 [95%CI = 0.19, 0.54]), and right hemisphere regions of interest (β = 0.52 [95%CI = 0.30, 0.72]). Longer time off diet was also positively associated with greater T1w/T2w changes. There was no evidence for the effects of gender or age at baseline.</p><p><strong>Conclusions: </strong>This study demonstrated significant increases in the T1w/T2w ratio in PKU patients as they resumed dietary control over a 12-month period. Raw Phe levels were not strongly associated with neuroimaging measures. These findings support the importance of lifelong treatment for PKU, and also demonstrate the potential reversibility of white matter changes in the disease.</p>","PeriodicalId":48964,"journal":{"name":"Acta Neuropsychiatrica","volume":" ","pages":"1-17"},"PeriodicalIF":2.5,"publicationDate":"2026-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147700632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunological Predictors in First-Episode Psychosis: Findings from One Year Prospective Follow-Up Study.","authors":"Talat Sarikavak, Özgür Özkalayci, Aytül Zerrin Sin, Emine Nihal Mete Gökmen, Damla Işman Haznedaroğlu, Hayriye Elbi","doi":"10.1017/neu.2026.10076","DOIUrl":"https://doi.org/10.1017/neu.2026.10076","url":null,"abstract":"<p><strong>Objective: </strong>Emerging evidence suggests that immune dysregulation may play a key role in the pathophysiology of psychosis. However, longitudinal studies integrating both innate and adaptive immune components in the same sample remain scarce. This study aimed to examine a broad spectrum of immunological parameters in first-episode psychosis (FEP) patients, both at onset and after treatment, in comparison to healthy controls.</p><p><strong>Methods: </strong>Thirty-two minimally treated FEP patients (no lifetime psychotropic exposure >1 month) and 26 healthy controls were assessed at baseline. 20 patients completed a follow-up approximately one year later. Immunological markers-including complete blood count(leukocyte, neutrophil, lymphocyte, monocyte), C-Reactive Protein(CRP), SAA, complement components (C3, C4), and immunoglobulins (IgG, IgA, IgM, IgE)-were measured at both time points. First-episode psychosis was confirmed using SCID (DSM-IV). Symptom severity was evaluated using PANSS and BPRS. ROC and logistic regression analyses were performed to assess predictive value.</p><p><strong>Results: </strong>Neutrophil, monocyte, C3, C4 levels and neutrophil-to-lymphocyte ratio(NLR) were significantly elevated in patients at both time points, with no change over time. CRP was elevated at T1 but normalized at follow-up. In contrast, immunoglobulin levels showed temporal and dimensional associations with symptom severity. NLR was correlated with negative symptoms during the acute phase, while IgG was associated with positive symptoms during remission. Elevated NLR and C4 predicted patient status in logistic regression analysis.</p><p><strong>Conclusion: </strong>This longitudinal study provides a system-level immunological profile across illness phases in FEP. The findings underscore distinct and dynamic contributions of innate and adaptive immunity to the onset and progression of psychosis.</p>","PeriodicalId":48964,"journal":{"name":"Acta Neuropsychiatrica","volume":" ","pages":"1-34"},"PeriodicalIF":2.5,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147678002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Parenteral clomipramine for depression or obsessive-compulsive disorder: a systematic review and meta-analysis.","authors":"Michael Ioannou, Örjan Falk, Joss Gustavsson, Johan Nilsson, Petteri Sjögren, Steinn Steingrimsson, Therese Svanberg, Zoltán Szabó, Susanna M Wallerstedt","doi":"10.1017/neu.2026.10074","DOIUrl":"10.1017/neu.2026.10074","url":null,"abstract":"<p><p>In severe cases of depression and obsessive-compulsive disorder (OCD), clomipramine is sometimes administered parenterally. This systematic review aimed to investigate whether parenteral clomipramine is superior to oral clomipramine or other treatments, primarily in terms of reducing depressive/OCD symptoms within two weeks (CRD420250654029). Medline, Embase, the Cochrane Library, and PsycInfo were searched for relevant publications. Randomized controlled trials (RCTs) without a high risk of bias formed the primary basis for the conclusions. Meta-analyses were performed when applicable. Certainty of evidence was assessed according to GRADE. The literature search identified 4973 unique publications, whereof 14 RCTs contributed data regarding the question at issue in this systematic review. The evidence synthesis revealed that parenteral clomipramine may not be superior to oral administration in terms of reducing depressive symptoms within two weeks, but a clinically relevant effect cannot be excluded (low certainty of evidence; five RCTs including 70 patients; mean difference of change in Hamilton depression rating scale scores (meta-analysis based on three RCTs): -1.27 (95% confidence interval: -3.09 to 0.54; 2, I2 = 22%). Regarding patients with OCD, no conclusion could be drawn (very low certainty of evidence; two RCTs including 47 patients; meta-analysis not conducted due to heterogeneity). Regarding comparisons with other treatments, the available RCT (depression) did not allow for conclusions, or no RCTs (OCD) were available. Current evidence indicates that parenteral administration of clomipramine may not be favourable compared to oral administration, and RCTs with relevant comparisons such as electroconvulsive therapy and ketamine are lacking.</p>","PeriodicalId":48964,"journal":{"name":"Acta Neuropsychiatrica","volume":" ","pages":"e30"},"PeriodicalIF":2.5,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13130327/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147678040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psilocybin Elicits a Conserved Glucocorticoid-Responsive Gene Signature Across Five 5-HT2A Receptor-Rich Brain Regions in Rat.","authors":"Ashkan Veysi, Daniela Atanasovski, Maryam Ardalan, Nasrin Motamed, Elias Eriksson","doi":"10.1017/neu.2026.10075","DOIUrl":"https://doi.org/10.1017/neu.2026.10075","url":null,"abstract":"<p><strong>Objective: </strong>Psychedelics such as psilocybin are known for their hallucinogenic properties and have also been reported to produce long-lasting therapeutic effects in depression and possibly also other psychiatric disorders. Several lines of evidence suggest that psilocybin exerts its effects through activation of 5-HT2A receptors located postsynaptically to serotonergic neurons, e.g., in the frontal cortex, parts of the limbic system, including the amygdala and hippocampus, and striatum. The present study was conducted to shed further light on psilocybin-induced changes in gene expression.</p><p><strong>Method: </strong>Samples from the medial prefrontal cortex, cingulate cortex, hippocampus, amygdala, and striatum were collected from 24 male Wistar rats 90 minutes after they had been injected with either saline or psilocybin (2 mg/kg) and subjected to multi-region transcriptional profiling using 3prime-RNASeq technology.</p><p><strong>Results: </strong><i>Nfkbia</i> and <i>Sgk1</i> were upregulated in all the studied regions, <i>Ddit4</i> was upregulated in four regions, and <i>Gpd1</i>, <i>Apold1</i>, <i>Sox9</i>, <i>Tsc22d3</i>, and <i>Slc2a1</i> were differentially expressed in two regions. Other cases of differentially expressed genes were region-specific.</p><p><strong>Conclusion: </strong>Whereas psilocybin was not found to alter the expression of genes encoding enzymes, transporters, or receptors implicated in the serotonergic signaling, or those specifically involved in the regulation of the synaptic activity of other neurotransmitters, a common denominator for many of the genes impacted by psilocybin is that they have previously been found to be activated by glucocorticoids.</p>","PeriodicalId":48964,"journal":{"name":"Acta Neuropsychiatrica","volume":" ","pages":"1-36"},"PeriodicalIF":2.5,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147647326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}